Disease · MONDO_0018177
glioblastoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. glioblastoma. Diseases, record MONDO_0018177. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0018177
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
GBM, GBM (glioblastoma), WHO grade IV glioma, brain tumor glioblastoma, glioblastoma (disease), glioblastoma multiforme, glioblastoma multiforme (disease), grade IV adult astrocytic tumor, grade IV astrocytic neoplasm, grade IV astrocytic tumor, grade IV astrocytic tumour, grade IV astrocytoma, primary glioblastoma multiforme, spongioblastoma multiforme
- Open Targets
Drugs453
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Approval | DailyMed and TTD | 425 | 423 | 423 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Approval | DailyMed | 145 | 144 | 144 | Drugs and targets |
| CARMUSTINE | CHEMBL513 | Small molecule | Approval | DailyMed and FDA | 31 | 28 | 28 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 3 | ClinicalTrials.gov | 42 | 42 | 42 | Drugs and targets |
| LOMUSTINE | CHEMBL514 | Small molecule | Phase 3 | ClinicalTrials.gov | 40 | 40 | 40 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 3 | ClinicalTrials.gov | 34 | 34 | 34 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 21 | 21 | 21 | Drugs and targets |
| IPILIMUMAB | CHEMBL1789844 | Antibody | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| SARGRAMOSTIM | CHEMBL1201670 | Protein | Phase 3 | ClinicalTrials.gov | 14 | 14 | 5 | Drugs and targets |
| AMINOLEVULINIC ACID | CHEMBL601 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 4 | Drugs and targets |
1 to 10 of 453
See all 453 drugsTargets469
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 24 | Epidermal growth factor receptor erbB1 antagonist; Epidermal growth factor receptor erbB1 binding agent; Epidermal growth factor receptor erbB1 cross-linking agent; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 vaccine antigen; Epidermal growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 23 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 16 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 15 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 15 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 15 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 12 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 3 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 11 | Platelet-derived growth factor receptor alpha antagonist; Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| ERBB2 | Epidermal growth factor receptor | 10 | Epidermal growth factor receptor inhibitor; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| TUBA1A | Tubulin | 10 | Tubulin disrupting agent; Tubulin inhibitor; Tubulin stabiliser | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
1 to 10 of 469
See all 469 targetsTrials1,058
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 29 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00304031 | Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma | Phase 3 | 1,173 | 2014-04-30 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00943826 | A Study of Bevacizumab (Avastin®) in Combination With Temozolomide and Radiotherapy in Participants With Newly Diagnosed Glioblastoma | Phase 3 | 921 | 2013-05-20 | Glioblastoma | BEVACIZUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03345095 | A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma | Phase 3 | 749 | 2024-01-31 | Newly Diagnosed Glioblastoma | MARIZOMIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02667587 | An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Phase 3 | 716 | 2022-02-03 | Brain Neoplasms | NIVOLUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02573324 | A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification | Phase 3 | 691 | 2023-05-11 | Glioblastoma, Gliosarcoma | DEPATUXIZUMAB MAFODOTIN | Its record names the disease | ClinicalTrials.gov |
| NCT00884741 | Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma | Phase 3 | 637 | 2016-10-12 | Glioblastoma, Gliosarcoma, Supratentorial Glioblastoma | BEVACIZUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | Phase 2 | 611 | 2025-11-17 | Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00482677 | Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme | Phase 3 | 562 | 2018-01-23 | Brain and Central Nervous System Tumors | TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02617589 | An Investigational Immuno-therapy Study of Nivolumab Compared to Temozolomide, Each Given With Radiation Therapy, for Newly-diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer) | Phase 3 | 560 | 2021-02-03 | Brain Cancer | NIVOLUMAB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00689221 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status | Phase 3 | 545 | 2014-11-04 | Glioblastoma | CILENGITIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 1,058
See all 1,058 trialsComparisons in its trials156
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bevacizumab + RT+Temozolomide vs Placebo + RT+Temozolomide: serious adverse events | 179 of 461 | 115 of 450 | 911 | NCT00943826 | Trial comparisons |
| Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: deaths from any cause | 263 of 358 | 255 of 358 | 716 | NCT02667587 | Trial comparisons |
| Radiotherapy, Temozolomide Plus Nivolumab vs Radiotherapy, Temozolomide Plus Placebo: serious adverse events | 259 of 355 | 217 of 354 | 709 | NCT02667587 | Trial comparisons |
| Experimental Arm vs Standard Arm: deaths from any cause | 55 of 309 | 57 of 307 | 616 | NCT03345095 | Trial comparisons |
Randomized Arm 1: TMZ+RT + Placebo vs Randomized Arm 2: TMZ+RT + Bevacizumab: Incidence of Grade 3 and Higher Treatment-related Toxicity as Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) Version 3.0 | 87 of 300 | 97 of 303 | 603 | NCT00884741 | Trial comparisons |
| Experimental Arm vs Standard Arm: serious adverse events | 114 of 305 | 80 of 297 | 602 | NCT03345095 | Trial comparisons |
| Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: deaths from any cause | 269 of 280 | 253 of 280 | 560 | NCT02617589 | Trial comparisons |
| Nivolumab + Radiation Therapy vs Temozolomide + Radiation Therapy: serious adverse events | 206 of 278 | 141 of 275 | 553 | NCT02617589 | Trial comparisons |
| Temozolomide vs Radiation: serious adverse events | 158 of 271 | 135 of 271 | 542 | NCT00482677 | Trial comparisons |
| Cilengitide + Temozolomide + Radiotherapy vs Temozolomide + Radiotherapy: serious adverse events | 138 of 263 | 115 of 258 | 521 | NCT00689221 | Trial comparisons |
1 to 10 of 156
See all 156 comparisons in its trialsPapers from its trials484
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0018177
GET https://conductscience.org/api/diseases/v1/MONDO_0018177/drugs?page=2